FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine

DUBLIN, Dec. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Ubrelvy (ubrogepant) for the acute treatment of migraine with or without...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news